Literature DB >> 20433206

Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.

Chenghong Lei1, Pu Liu, Baowei Chen, Yumeng Mao, Heather Engelmann, Yongsoon Shin, Jade Jaffar, Ingegerd Hellstrom, Jun Liu, Karl Erik Hellstrom.   

Abstract

We report that antibodies can be spontaneously loaded in functionalized mesoporous silica (FMS) with superhigh density (0.4-0.8 mg of antibody/mg of FMS) due to their comprehensive noncovalent interaction. The superhigh loading density and noncovalent interaction between FMS and antibodies allow long-lasting local release of the immunoregulatory molecules from FMS under physiological conditions. Preliminary data indicate that FMS-anti-CTLA4 antibody injected directly into a mouse melanoma induces much greater and extended inhibition of tumor growth than the antibody given systemically. Our findings open up a novel approach for local delivery of therapeutically active proteins to tumors and, potentially, other diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433206      PMCID: PMC2874126          DOI: 10.1021/ja102414t

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  10 in total

1.  Entrapping enzyme in a functionalized nanoporous support.

Authors:  Chenghong Lei; Yongsoon Shin; Jun Liu; Eric J Ackerman
Journal:  J Am Chem Soc       Date:  2002-09-25       Impact factor: 15.419

2.  Probing mechanisms for enzymatic activity enhancement of organophosphorus hydrolase in functionalized mesoporous silica.

Authors:  Baowei Chen; Chenghong Lei; Yongsoon Shin; Jun Liu
Journal:  Biochem Biophys Res Commun       Date:  2009-10-27       Impact factor: 3.575

3.  Characterization of functionalized nanoporous supports for protein confinement.

Authors:  Chenghong Lei; Yongsoon Shin; Jon K Magnuson; Glen Fryxell; Linda L Lasure; Douglas C Elliott; Jun Liu; Eric J Ackerman
Journal:  Nanotechnology       Date:  2006-10-25       Impact factor: 3.874

4.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

5.  Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores

Authors: 
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

Authors:  Zhengmao Ye; Ingegerd Hellström; Martha Hayden-Ledbetter; Amber Dahlin; Jeffrey A Ledbetter; Karl Erik Hellström
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 7.  Vaccines to treat cancer--an old approach whose time has arrived.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Cell Biochem       Date:  2007-10-01       Impact factor: 4.429

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 9.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

10.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

  10 in total
  22 in total

1.  Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Authors:  Min Dai; Yuen Yee Yip; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

Review 2.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 3.  Nanomedicine approaches to improve cancer immunotherapy.

Authors:  Hui Qiu; Yuanzeng Min; Zach Rodgers; Longzhen Zhang; Andrew Z Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-10

Review 4.  Delivering nanomedicine to solid tumors.

Authors:  Rakesh K Jain; Triantafyllos Stylianopoulos
Journal:  Nat Rev Clin Oncol       Date:  2010-09-14       Impact factor: 66.675

5.  Nanoparticle preconditioning for enhanced thermal therapies in cancer.

Authors:  Mithun M Shenoi; Neha B Shah; Robert J Griffin; Gregory M Vercellotti; John C Bischof
Journal:  Nanomedicine (Lond)       Date:  2011-04       Impact factor: 5.307

Review 6.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 7.  Synthetic immune niches for cancer immunotherapy.

Authors:  Jorieke Weiden; Jurjen Tel; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

8.  Intramesoporous silica structure differentiating protein loading density.

Authors:  Wen Qi; Xiaolin Li; Baowei Chen; Pei Yao; Chenghong Lei; Jun Liu
Journal:  Mater Lett       Date:  2012-05-15       Impact factor: 3.423

9.  Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Authors:  Min Dai; Huafeng Wei; Yuen Yee Yip; Qinghua Feng; Kecheng He; Viorica Popov; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

Review 10.  Nanomaterials for cancer immunotherapy.

Authors:  Wantong Song; Sara N Musetti; Leaf Huang
Journal:  Biomaterials       Date:  2017-09-17       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.